Office of Medical Education, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA.
Office of Medical Education, Alabama College of Osteopathic Medicine, Dothan, AL, USA.
Clin Pediatr (Phila). 2024 Nov;63(11):1579-1584. doi: 10.1177/00099228241236033. Epub 2024 Mar 10.
Cow's milk protein allergy (CMPA) affects 2% to 3% of infants and is managed with hypoallergenic formulas. The 2022 recalls of infant formulas due to factors including contamination led to specialty formula shortages, highlighting CMPA management challenges. Understanding health care providers' (HCPs) decision-making in transitioning to alternative formulas during shortages is crucial. Limited attention has been given to how pediatric physicians make these choices. This study utilized US HCPs' de-identified survey data to assess driving factors when switching extensively hydrolyzed formulas during shortages. A total of 104 eligible HCPs participated, including general pediatrics, pediatric allergy/immunology, and pediatric gastroenterology specialists. Safety, tolerability, and efficacy were identified as top factors for switching formulas. Formula 1 was considered well-tolerated, patient-accepted, and safe by all HCPs. Most expressed strong belief in Formula 1's safety and effectiveness. Findings inform CMPA management during shortages, offering guidance to HCPs for suitable formula selection and enhanced infant care.
牛奶蛋白过敏（CMPA）影响 2%至 3%的婴儿，采用低敏配方进行管理。由于污染等因素，2022 年婴儿配方奶粉召回导致特医配方短缺，突显了 CMPA 管理挑战。了解卫生保健提供者（HCPs）在短缺期间转用替代配方时的决策至关重要。儿科医生如何做出这些选择的关注有限。本研究利用美国 HCPs 的匿名调查数据，评估在短缺期间转换深度水解配方时的驱动因素。共有 104 名符合条件的 HCPs 参与，包括普通儿科医生、儿科过敏/免疫学专家和儿科胃肠病学专家。安全性、耐受性和疗效被确定为转换配方的首要因素。所有 HCPs 均认为配方 1 耐受性良好、患者接受且安全。大多数人强烈相信配方 1 的安全性和有效性。研究结果为短缺期间的 CMPA 管理提供了信息，为 HCPs 提供了合适配方选择和加强婴儿护理的指导。
